Artemisinin based anti malarial drugs becoming resistant to malaria

Malaria parasites in western Cambodia have become resistant to artemisinin based therapies, the first-line treatment for malaria, revealed by researchers.

The study is published in the New England Journal of Medicine. Resistance to the drugs makes them less effective and could eventually render them obsolete, putting millions of lives at risk.

Signs of artemisinin resistance have been reported in the region already, but this new research is the first detailed study of the problem. The study was funded by the Wellcome Trust, the Li Ka Shing Foundation, and the Global Malaria Programme of the World Health Organisation (through grants from the Bill and Melinda Gates Foundation and the Western Pacific Regional Office).

Malaria is a potentially deadly disease that kills more than a million people each year, mainly young children and pregnant women. It is caused by malaria parasites, which are injected into the bloodstream by infected mosquitoes. The most deadly form, Plasmodium falciparum, is responsible for nine out of ten deaths from malaria.

The most effective anti-malarial drug is artemisinin, derived from Artemisia annua, also known as sweet wormwood, which had been used in Chinese medicine for centuries under the name Qinghaosu. It was rediscovered in the 1970s, evaluated first in South-East Asia, and eventually accepted as an essential component of antimalarial treatment in the past few years. The artemisinin derivatives have the advantage over other anti-malarial drugs, such as chloroquine and mefloquine, in having few side effects and ??" until now ??" malaria parasites have no resistance against it.

Although the drugs ??" most commonly in the form of the derivative artesunate ??" can be used on their own as a monotherapy, fears over the possible development of resistance mean that they are usually given in conjunction with one or more other drugs as artemisinin-based combination therapies (ACTs), now recommended by the WHO as the first-line treatment for uncomplicated falciparum malaria in all endemic countries.

Following increasing reports that the efficacy of artemisinin monotherapies and combination therapies were declining in western Cambodia, researchers at the Wellcome Trust-Mahidol University Oxford Tropical Medicine Research Programme, based in Bangkok, studied the susceptibility of P. falciparum parasites to the drugs. The Research Programme is a collaboration between Mahidol University, Bangkok, and the University of Oxford, supported by the Wellcome Trust.

The researchers studied forty patients in each of Pailin, western Cambodia, and Wang Pha, north-western Thailand. In two open-label, randomised trials, each was given the relevant dosage appropriate to their body weight of either artesunate or a combination of artesunate and mefloquine.

On average, patients in Thailand were clear of parasites in 48 hours; in western Cambodia this took 84 hours ??" in other words, it took almost twice as long to clear the parasites in Cambodia as it did in Thailand.

During the treatment period, as the number of parasites in the blood falls, so the infection should clear. Its recurrence can be a sign that the drug treatment is not working effectively.

In this study, out of the twenty patients treated with the monotherapy in each country, there were recurrences of the infection in six patients in western Cambodia compared to just one person in Thailand. Of the twenty patients treated with the combination therapy, infection recurred in two patients in Cambodia compared to one in Thailand. These results again suggest that artemisinin was less effective on the Cambodian parasites.

"Our study suggests that malaria parasites in Cambodia are less susceptible to artemisinin than those in Thailand," says Dr Arjen Dondorp, lead author of the study. "This means that it takes longer to kill the parasites. Artemisinin should clear the parasites at an early stage, preventing them further maturing and reproducing. When the drug's action is impaired, it becomes more difficult to eliminate the parasites from the body.

"With artesunate losing its potency, ACTs rely much more on the weaker partner drug, increasing the risk that resistance also evolves towards the partner drug. This has very important consequences for the lifespan of ACTs. Losing ACTs would be a disaster for malaria control."

"Artemisinins are essential weapons in our war against malaria," he says. "If they become ineffective, we have no immediate replacement. The consequences could be devastating. Elimination of malaria will not be possible and millions of lives could be lost."

(Anil Kumar -- sub-editor compiled and published Artemisinin based anti malarial drugs becoming resistant to malaria at HealthNewsTrack on July 30, 2009 sourced from Wellcome Trust -

Malaria - recent articles and current news stories:

- Infected female malaria mosquitoes more attracted to human odour
- Bed nets use could eradicate malaria
- Cell phone data helps to curb spread of malaria
- Poor quality or fake malaria drugs pose threat
- New malaria vaccine may make all strains of malaria parasite ineffective

Most related articles:

- Artemisinin based anti malarial drugs becoming resistant to malaria
- Novel anti malarial drug candidate found - 12
- Malaria during pregnancy first trimester - antimalarial is safe - 11.5
- New drug aims to transform malaria treatment - 9.6
- Poor quality or fake malaria drugs pose threat - 9.2

More related articles:

- Artemisinin, Anti malarial, Malaria, Parasite, Malaria parasite, Mosquitoes, Plasmodium falciparum, Artemisia, Falciparum malaria
- Infected female malaria mosquitoes more attracted to human odour - 36
- Malaria during pregnancy first trimester - antimalarial is safe - 32.6
- Promising candidates for malaria vaccine revealed - 30.4
- New lead on malaria treatment - 29

Malaria related articles:

- Zambian success in fight against malaria - 6.1
- 125.2 million pregnant women at risk of malaria - 6
- Malaria during pregnancy first trimester - antimalarial is safe - 5.2
- Promising candidates for malaria vaccine revealed - 5
- Malaria cases rising in UK - 5

Malaria article/news source:

Read more health articles from Wellcome Trust and health articles from UK.

Malaria - search related terms:

Anti malarial, Artemisia, Artemisinin, Falciparum malaria, Malaria, Malaria parasite, Mosquitoes, Parasite, Plasmodium falciparum,
Health Newstrack is dedicated to serve recent and updated health & medical research, events/news, views/reviews to its subscribers and free access to general public, health & medical professionals, and other health seekers worldwide online with a user-friendly system. Track health news daily at Health Newstrack.
Subscribe: rss | email

Top sections:
Health (189)
Breast cancer (169)
Healthcare (134)
HIV (130)
Obesity (126)
Pregnancy (115)
Diabetes (102)
Swine Flu (97)
Heart disease (86)
Prostate Cancer (86)
Smoking (81)
Alzheimer's Disease (79)
Cancer (75)
Depression (61)
Autism (53)

Current news
Threat of resistance to artemisinin-based anti-malarial drugs highlighted by new study

What is Malaria?
About Malaria -- Malaria is an infectious disease characterized by cycles of chills, fever, and sweating, caused by a protozoan of the genus Plasmodium in red blood cells, which is transmitted to humans by the bite of an infected female anopheles mosquito.

List health news, Health organizations, Health news world, Glossary     Go to top

The information provided on Health Newstrack is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. We comply with the HONcode principles for trustworthy health information, and Health News Track is hon code accredited, verify here.
About us, Site map Privacy policy, Disclaimer
© 2015
Health Newstrack - Track Health News Daily at Our Newstrack on Health News provides latest health news, medical news, and health articles with recent health & medical updates.